We innovate game changing medical technologies.
We advance innovations into production within market-specific ventures.
We build partnerships for global commercialization.
Market-specific Octane companies empowered to develop and launch our latest innovations.
Our body’s natural processes and materials are highly efficient at repairing damage and restoring normal function. Octane innovations work at the cellular level to harness and accelerate these inherent healing abilities, with the goal of achieving sustained therapeutic benefits that surpass conventional therapies.
It’s regenerative medicine at its best. Together with our partners, we’re working at the highest levels of creativity to develop, manufacture and commercialize the most advanced bioprocesses, biomaterials and bioreactors. Our goal: to make regenerative medicine the new standard of care.
March 2, 2022
Octane HyperPEEK® offers breakthrough biocomposite for enhanced bone regeneration
Kingston, Ontario, June 2, 2022 – Octane Exo Inc., an Octane Medical Group venture, has achieved a breakthrough in medical implant technology with Octane HyperPEEK, an advanced biocomposite proven to enhance bone regeneration with the goal of enhanced integration and stability.
December 15, 2020
Octane Completes Major Expansion of State-of-the-Art Facility in Kingston, Ontario
Kingston, Ontario, 15 December 2020 – Octane Medical Group has expanded its state-of-the-art facility in Kingston, Ontario Canada. The 40,000-square-foot building, which Octane purchased in 2011, houses the company's head office and features regulated biolabs for biomaterial and biologics discovery programs including cell therapy research and development, a ...
March 18, 2020
Octane Wins 2020 Edison Award in Cellular Research for AUTOGRAFTA™ Synthesis of Living Grafts for Skeletal Reconstruction
Maine, USA, 18 March 2020 – Octane innovations in tissue engineering, personalized medicine and automated living implant production have earned one of the highest Edison Awards, winning Gold in the Medical / Dental Cellular Research category. The Gold award recognizes AUTOGRAFTA™ living graft technology and the ability to ...
October 29, 2018
Lonza Acquires a Controlling Stake in Octane Biotech to Further Develop Cocoon™ Autologous Technology
Basel, Switzerland, 29 October 2018 – Lonza announced today the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane ...